Sandro Grelli is Principal Investigator for the Infectious diseases, host immunity and drugs discovery
Prof. Sandro Grelli, MD. Associate Professor of Microbiology and Clinical Microbiology, University of Rome Tor Vergata. Since 2018, he coordinates the Virology Unit and currently participates in the Task Force COVID19 of Tor Vergata Hospital. Director of Specialization degree in Microbiology and Virology. President of the degree course in “Biomedical laboratory diagnostic techniques”. Member of the Scientific Committee of the PhD course in “Microbiology, immunology, infectious diseases, transplantation and related disease (MIMIT)”. He works on different research and multicentre clinical projects regarding infectious diseases, host immune response and novel drugs discovery. Editor, Cell Death Disease (www.nature.com/cddis) (IF 6.1).
Matteucci C, et al. Inhibition of IκBα phosphorylation potentiates regulated cell death induced by azidothymidine in HTLV-1 infected cells. Cell Death Discovery 2020 Feb 18; 6:9
Balestrieri E, et al. Endogenous Retroviruses Activity as a Molecular Signature of Neurodevelopmental Disorders. Int J Mol Sci. 2019 Nov 30;20(23):6050.
Marino-Merlo F, Papaianni E, Frezza C, et al. NF-κB-Dependent Production of ROS and Restriction of HSV-1 Infection in U937 Monocytic Cells. Viruses. 2019;11(5):428.
Cipriani C, Ricceri L, Matteucci C, et al. High expression of Endogenous Retroviruses from intrauterine life to adulthood in two mouse models of Autism Spectrum Disorders. Sci Rep. 2018;8(1):629.
Macchi B, Balestrieri E, Frezza C, et al. Quantification of HTLV-1 reverse transcriptase activity in ATL patients treated with zidovudine and interferon-α. Blood Adv. 2017;1(12):748–752.